news

Fibrinogen Technology in exclusive license for Fibriant

30 Sep 2015

Fibriant B.V., a developer of innovative fibrinogen technology, announced that it has concluded an exclusive license agreement with TNO to allow the company to further build its unique fibrinogen technology platform.

Links Jaap Koopman en rechts Niek Snoeij

Fibrinogen is an essential part of nature’s own injury-repair and defense mechanism, and occurs in blood in many different forms and shapes. Each variant has its own specific properties, and the ability to form fibrin networks with different structures and functions. This natural variation in fibrinogen, in both form and function, provides the key to creating improved solutions for a wide range of healthcare applications. The versatility of Fibriant’s technology platform enables the company to produce specific fibrinogen variants, either by sub-fractionation of human plasma fibrinogen, or by recombinant production in mammalian cells.

Jaap Koopman, Ph.D., Chief Executive Officer, said: “The TNO license provides broad protection and significantly enhances our competitive position in the rapidly growing fibrinogen market. Fibriant was recently founded by a small group of experts in the fibrinogen field with a strong track record in industry and academia. For our own proprietary product pipeline as well as for third parties we aim to develop specific fibrinogen variants for tissue repair, remodeling and regeneration, and tools to further explore the role of fibrinogen in inflammation and immune response.”

Niek Snoeij, Director of TNO’s Healthy Living focus area, said: “TNO is excited to support this new Dutch start-up company by providing the license that underpins its fibrinogen technology platform. It is part of TNO’s mission to support companies like Fibriant that form the backbone of the knowledge economy, and are instrumental in creating new economic activities in the Netherlands.”

Roadmap

Predictive Health Technologies: better understanding of health and diseases

With increasing life expectancy the costs of healthcare are drastically rising, especially in the last years of life. By better understanding the biology of health and diseases, we can address the effectiveness... Read more
Zie ook

We use anonymous cookies to enhance the use of our site.